GlassScriptPhysician profile
Hollace D Leppert
NPI 1912905902
$3,561.39
in general payments reported to CMS, 2019-2025
32 companies · $20.25 in 2025
The $20.25 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $812 · 2021: $731 · 2022: $488 · 2023: $491 · 2024: $299 · 2025: $20.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $962.33 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $415.66 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $380.00 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $223.80 | 2019-2024 | Xarelto |
| Abbvie INC. | $198.03 | 2021-2023 | |
| Allergan, INC. | $154.73 | 2020 | |
| Lilly USA, LLC | $133.81 | 2020-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $130.03 | 2020-2021 | |
| Amgen INC. | $112.57 | 2019-2024 | Evenity, Prolia |
| Astellas Pharma US INC | $102.90 | 2019-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.62 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $75.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $64.80 | 2019-2023 | Pneumovax 23, Vaxneuvance |
| Kowa Pharmaceuticals America, INC. | $52.36 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.19 | 2020-2024 | Camzyos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37.55 | 2021-2022 | |
| Axsome Therapeutics, INC. | $34.11 | 2024 | Auvelity |
| Ibsa Pharma INC. | $34.07 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.67 | 2022 | |
| Dexcom, INC. | $30.43 | 2021-2022 | |
| Eisai INC. | $30.09 | 2020 | |
| Daiichi Sankyo INC. | $27.81 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.28 | 2022 | |
| Esperion Therapeutics, INC. | $20.74 | 2020 | |
| Horizon Therapeutics Plc | $17.94 | 2020 | |
| Genentech USA, INC. | $17.43 | 2019 | |
| Boston Scientific Corporation | $16.75 | 2020 | |
| Almatica Pharma LLC | $16.01 | 2022 | |
| Sanofi Pasteur INC. | $14.63 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hollace Leppert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.